genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2021
Antisense RNA
Insights
n-Lorem Makes Ultrarare Disease Treatment Personal
Julianna LeMieux, PhD
-
April 15, 2021
0
Drug Discovery
Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B
Alex Philippidis
-
October 7, 2019
0
Drug Discovery
$4.1M Nant Investment in Benitec Supports Joint Antisense RNA Program for HNSCC
GEN Staff Writer
-
March 13, 2017
0
News
OliPass, BMS Enter Antisense Drug Development Agreement
GEN Staff Writer
-
October 28, 2014
0
News
Biogen Idec Pays Isis $3.5M for Antisense Drug Milestone
GEN Staff Writer
-
May 10, 2013
0
News
Mystery Rare Disease Drug Earns Isis $5M from GSK
GEN Staff Writer
-
February 19, 2013
0
Industry News
Prosensa Raises €23M to Progress Exon-Skipping Antisense Oligonucleotides
GEN Staff Writer
-
January 25, 2012
0
Scroll Up
Scroll Up
